Allele and genotype frequencies of CYP2C19 in Sudanese patients undergoing percutaneous coronary intervention
DOI:
https://doi.org/10.56511/JIPBS.2022.v9.i02.pp36-42Abstract
Genetic variations among different ethnic groups result in variation of drug response. Several studies reported association between these variants and reduction of enzymatic function. Cytochrome P450, specifically CYP2C19 represent a major contributor in this variability. The present study aimed to determine the prevalence of CYP2C19 variants in Sudanese patients undergoing percutaneous coronary intervention (PCI).This prospective observational cohort study recruited 197 Sudanese patients with PCI taking clopidogrel from Wad Medani Heart Diseases and Surgery Center. Patients were genotyped for CYP2C19*2 and CYP2C19*3 using ASP-PCR and PCR-CTPP respectively. The frequency of CYP2C19*2, and *3 was 15%, and 1% respectively. The wild type (*1/*1) was the most frequent CYP2C19 *2 alleles (71.6%), followed by heterozygous mutant (*1/*2) 25.9%, and the least frequent was homozygous mutant (*2/*2) 2.5%. For CYP2C19 * 3, the wild type allele was the most frequent (98.0%), followed by heterozygous mutant (*1/*3) 2% and 0% for homozygous mutant(*3/*3). The overall distribution of CYP2C19 genotype revealed that 69.0% of patients were carriers of homozygotes wild allele (*1/*1); 28.4% were carriers of heterozygotes mutants (1*/2*&1*/3*), and 2.5% were carriers homozygotes mutant (2*/2*). Thus, 69.0% were classified as extensive metabolizers (EMs), 28.4% intermediate metabolizers (IMs) and 2.5% poor metabolizers (PMs). The finding of the present study was comparable to that obtained from several studies conducted in Arabs and African population. The wild type allele was the most prevalent, followed by heterozygotes mutants, and the least was homozygotes mutant. Accordingly the most frequent predicted phenotype was EMs followed by IMs and the least frequent was PMs
Keywords:
CYP2C19, Wilde type allele, Heterozygotes mutants, Homozygotes mutantsDownloads
References
Rainone A, De Lucia D, Morelli C, Valente D, Catapano O, Caraglia M. Clinically relevant of cytochrome P450 family enzymes for drug - drug interaction in anticancer therapy. World Can cer Research Journal. 2015 ; 2(2):524.
Wei YQ, Wang DG, Yang H, Cao H. Cytochrome P450 CYP 2C19* 2 associated with adverse 1 - year cardiovascular events in patients with acute coronar y syndrome. PLoS One. 2015 ; 10(7):e0132561.
Amin AM, Sheau Chin L, Azri Mohamed Noor D, SK Abdul Kader MA, Kah Hay Y, Ibrahim B. The personalization of clopidogrel antiplatelet therapy: the role of integrative pharmacogenetics and pharmacometabolomics. Cardiology research and practice. 2017 ; 2017.
Fox CS, Hall JL, Arnett DK, Ashley EA, Delles C, Engler MB, Freeman MW, Johnson JA, Lanfear DE, Liggett SB, Lusis AJ. American Heart Association Council on Functional Geno mics and Translational Biology, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, Council on Quality of Care and Outcomes Research, and Council on Epidemiology and Prevention. Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association. Circulation. 2015; 131:1715 - 36.
Scott SA, Sangkuhl K, Shuldiner AR, Hulot JS, Thorn CF, Altman RB, Klein TE. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmac ogenetics and genomics. 2012 ; 22(2):159.
Luzum JA, Pakyz RE, Elsey AR, Haidar CE, Peterson JF, Whirl ‐ Carrillo M, Handelman SK, Palmer K, Pulley JM, Beller M, Schildcrout JS. The pharmacogenomics research network translational pharmacogenetics program: outcomes and metrics of pharmacogenetic implementations across diverse healthcare systems. Clinical Pharm acology & Therapeutics. 2017 ; 102(3):502 - 10.
Jeong YH, Bliden KP, Park Y, Tantry US, Gurbel PA. Pharmacogenetic guidance for antiplatelet tr eatment. The Lancet. 2012 ; 380(9843):725.
Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clinical Pharm acology & Therapeutics. 2013 ; 94(3):317 - 23.
Lauschke VM, Milani L, Ingelman - Sundberg M. Pharmacogenomic biomarkers for improved drug therapy — recent progress and future developm ents. The AAPS journal. 2018 ; 20(1):1 - 6.
Samer CF, Lorenzini K, Rollason V, Daali Y, Desme ules JA. Applications of CYP450 testing in the clinical setting. Molecular diagnosis & therapy 2013; 17(3):165 - 84.
Angiolillo DJ, Fernandez - Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, Costa MA. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. Journal of the American College of Ca rdiology. 2007; 49(14):1505 - 16.
Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, Gaussem P. Cytochrome P450 2C19 loss - of - function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006 ; 108(7):2244 - 7.
Bundock PC, Cross MJ, Shapter FM, Henry RJ. Robust allele - specific polymerase chain reaction markers developed for single nucleotide polymorphisms in expressed barley sequences. Theoretica l and Applied Genetics. 2006 ; 112(2):358 - 65.
Hamajima N, Saito T, Matsuo K, Kozaki KI, Takahashi T, Tajima K. Polymerase chain reaction with confronting two ‐ pair primers for polymorphism genotyping. Japanese Jour nal of Cancer Research. 2000 ; 91(9):865 - 8.
Solé X, Guinó E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association stu dies. Bioinformatics. 2006 ; 22(15):1928 - 9.
Sistonen J, Fuselli S, Palo JU, Chauhan N, Padh H, Sajantila A. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacog enetics and genomics. 2009 ; 19(2):170 - 9.
Chaudhry AS, Kochhar R, Kohli KK. Genetic polymorphism of CYP2C19 & therapeutic response to proton pump inhibitors. Indi an J Med Res. 2008 ; 127(6):521 - 30.
Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Cli nical pharmacokinetics. 2002 ; 41(12):913 - 58.
Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annual review of pharm acology and toxicology. 2001 ; 41(1):815 - 50.
Abbas A, Malik S, Sulieman B, Enan K. Detection of CYP2C19* 2_ allele among Helicobacter pylori - infected patients in two tertiary hospitals of Khartoum, Sudan, 2019. F1000Research. 2021 ; 10(1063):1063.
Ayesh BM, Al - Astal IR, Yassin MM. The clinical effects of CYP2C19* 2 allele frequency on Palestinian patients receiving clopidogrel after percutaneous coronary intervention. International Journa l of Clinical Pharmacy. 2019 ; 41(1):96 - 103.
Geisler T, Schaeffeler E, Dippon J, Winter S, Buse V, Bischofs C, Zuern C, Moerike K, Gawaz M, Schwab M. CYP2C19 and non - genetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics 2008; 9(9): 1251 - 1259.
Pedersen RS, Brasch - Andersen C, Sim SC, Bergmann TK, Halling J, Petersen MS, Weihe P, Edvardsen H, Kristensen VN, Brøsen K, Ingelman - Sundberg M. Linkage disequilibrium between the CYP2C19* 17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. European journal of clinical pharmacology. 2010 ; 66(12):1199 - 205.
Persson I, Aklillu E, Rodrigues F, Bertilsson L, Ingelman - Sundberg M. S - mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopia ns. Pharmacogenetics. 1996 ; 6(6):521 - 6.
Djaffar Jureidini I, Chamseddine N, Keleshian S, Naoufal R, Zahed L, Hakime N. Prevalence of CYP2C19 polymorphisms in the Lebanese population. Mol ecular biology reports. 2011 ; 38(8):5449 - 52.
Yousef AM, Bulatova NR, Newman W, Hakooz N, Ismail S, Qusa H, Zahran F, Anwar Ababneh N, Hasan F, Zaloom I, Khayat G. Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population. Mol ecular biology reports. 2012 ; 39(10):9423 - 33.
Zalloum I, Hakooz N, Arafat T. Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19* 1 and CYP2C19* 2 on the pharmacokinetic profile of lansoprazole. Mol ecular biology reports. 2012 ; 39(4):4195 - 200.
Aynacioglu AS, Sachse C, Bozkurt A, Kortunay S, Nacak M, Schröder T, Kayaalp SO, Roots I, Brockmöller J. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clinical Pharm acology & Therapeutics. 1999; 66(2):185 - 92.
Abid L, Laroussi L, Bahloul A, Siala A, Abdelhédi R, Kharrat N, Hentati M, Kammoun S. Impact of cytochrome P450 2C19* 2 polymorphism on the clinical cardiovascular events after stent implantation in patients receiving clopidogrel of a southern Tunisian region. World Journal of Cardiovascular Diseases. 2013; 3 (1): 4 - 10.
Saeed LH, Mayet AY. Genotype - Phenotype analysis of CYP2C19 in healthy Saudi individuals and its potential clinical implication in drug therapy. International journal of medical sciences. 2013; 10(11):1497 - 502.
Hamdy SI, Hiratsuka M, Narahara K, El ‐ Enany M, Moursi N, Ahmed MS, Mizugaki M. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. British journal of clinical pharmacology. 2002 ; 53(6):596 - 603.
Herrlin K, Massele AY, Jande M, Alm C, Tybring G, Abdi YA, Wennerholm A, Johansson I, Dahl ML, Bertilsson L, Gustafsson LL. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clinical Pharm acology & Therapeutics. 1998 ; 64(4):391 - 401.
Luo HR, Poland RE, Lin KM, Wan YJ. Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: A cross ‐ ethnic comparative study. Clinical Pharm acology & Therapeutics. 2006 ; 80(1):33 - 40.
Al ‐ Jenoobi FI, Alkharfy KM, Alghamdi AM, Bagulb KM, Al ‐ Mohizea AM, Al ‐ Muhsen S, Halwani R, Parvez MK, Al ‐ Dosari MS. CYP2C19 genetic polymorphism in Saudi Arabians. Basic & clinical pha rmacology & toxicology. 2013 ; 112(1):50 - 4.
Kudzi W, Dodoo AN, Mills JJ. Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population . BMC medical genetics. 2009 ; 10(1):1 - 6.
Dandara C, Mutowembwa Masimirembwa C, Magimba A, Sayi J, Kaaya S, Sommers DK, Snyman JR, Hasler JA. Genetic polymorphism of CYP2D6 and CYP2C19 in east - and southern African populations including psychiatric patients. European journal of clinical pharmacology. 2001; 57(1):11 - 7.
Scott S, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, Roden DM, Klein TE, Shuldiner AR. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 – 2C19 (CYP2C19) ge notype and clopidogrel therapy. Clinical Pharmacology & Therapeutics. 2011; 90(2):328 - 32.
Published
How to Cite
Issue
Section
Copyright (c) 2022 Tahani Hassan Ibrahim, Imad Eldin Mohamed Tag Eldin, Abd Elwahab Hassan Mohamed, Ameer Mohamed Dafalla, Abdalla Karem Gibreel, Adil Mergani
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Journal of Innovations in Pharmaceutical and Biological Sciences is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Based on a work at